The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.

Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.

The present invention provides a solid composition comprising nanoparticles comprising at least one water-insoluble active and at least one oil, dispersed within a water-soluble mixture of at least one hydrophilic polymer and at least one surfactant. Process for preparing such solid compositions and aqueous dispersions of such compositions are also provided.

The invention relates to an additive for a powder material intended for compaction into shaped bodies. The additive is used to influence the powder material with regard to its cohesion and slidability on foreign surfaces and comprises as the main constituent one or more polyglycerol fatty acids, each obtained by way of a complete or partial esterification of a linear or branched polyglycerol containing two to eight glyceryl units with one or more fatty acids, each containing 6 to 22 carbon atoms.

The disclosure provides for pharmaceutical compositions comprising an alginate salt, such as sodium alginate. The disclosure further provides for processes and methods for making pharmaceutical compositions. In yet a further aspect, the disclosure provides for methods of utilizing a pharmaceutical composition for treatment of acid reflux diseases. In another aspect, the disclosure provides for formulations suitable for oral use in dosage forms of capsules and dry powders.

A preparation containing a mixture of at least one phospholipid, and at least one fatty acid salt of a cation with an anion derived from a fatty acid. A method for preparing such preparation and the use of such preparation to provide polyunsaturated fatty acids to cells, tissues, organs or organisms, for example in the field of cell and tissue culture, organ preservation, human or animal nutrition, or cosmetics.

Formulations of Nebivolol are provided. One formulation includes 0.05 to 10% (w/w) of Nebivolol or a pharmaceutically acceptable salt thereof, 0.4 to 10% (w/w) of a solubilizer, and 5 to 90% (w/w) of a sweetener. The formulation has a pH in the range of 3 to 7. A reconstituted formulation including the formulation with a liquid vehicle is also provided. Also provided are processes of preparing the formulations.

The invention relates to a solid Δ.sup.9-THC composition containing Δ.sup.9-THC and a powder former and having a molar ratio of Δ.sup.9-THC to powder former to form a flowable Δ.sup.9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, β-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid Δ.sup.9-THC composition of the invention. The Δ.sup.9-THC may be synthetic Δ.sup.9-THC or may be extracted Δ.sup.9-THC. The invention provides pharmaceutical or nutraceutical composition containing a solid Δ.sup.9-THC composition of the invention and a pharmaceutically- or nutraceutically-acceptable carrier where Δ.sup.9-THC is present in a pharmaceutically or nutraceutically effective amount. The invention also provides methods of treating a disease, disorder, or condition by administering to a patient in need thereof a therapeutically effective amount of a solid Δ.sup.9-THC composition. A solid Δ.sup.9-THC composition of the invention may also be incorporated into food and beverage products.

Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.